Research programme: anti-HER3 monoclonal antibody - MedImmuneAlternative Names: MEDI-3379
Latest Information Update: 30 Oct 2013
At a glance
- Originator MedImmune
- Class Monoclonal antibodies
- Mechanism of Action ERBB-3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 20 Oct 2013 Preclinical trials in Breast cancer in USA (Parenteral)